Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TACR3 | P29371 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186416 | 1.00 | LMNA (0.61) | LMNAALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL186230 | 1.00 | LMNA (0.61) | LMNAALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL2022347 | 0.86 | ALDH1A1 (0.63) | LMNAALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL3370482 | 0.86 | ALDH1A1 (0.63) | LMNAALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL15093820 | 0.86 | EPHX2 (0.65) | LMNAALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL3376152 | 0.86 | ALDH1A1 (0.63) | LMNAALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL12707522 | 0.85 | LMNA (0.58) | LMNAALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL12293909 | 0.85 | LMNA (0.58) | LMNAALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL12707520 | 0.85 | LMNA (0.58) | LMNAALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL184883 | 0.85 | KMT2A (0.50) | LMNAALDH1A1KDM4EHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2401260-A1 | DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | Galderma Research & Development (FR) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010097465-A1 | DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-09-02 | — | — | WO | disclosed |
| EP-1279660-B1 | Process for producing an optically active amide from an alpha, beta-unsaturated amide derivative in the presence of an optically active transition metal complex containing a phosphine-phosphorane compound and rhodium | TAKASAGO PERFUMERY CO LTD (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-6855847-B2 | Process for producing optically active amide from α β- unsaturated amide derivative in the presence of transition metal complex containing phosphine-phosphorane compound and transition metal | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20030120067-A1 | Process for producing optically active amide from alpha beta- unsaturated amide derivative in the presence of transition metal complex containing phosphine-phosphorane compound and transition metal | TAKASAGO INTERNATIONAL CORPORATION | 2003-06-26 | — | — | US | disclosed |
| EP-1279660-A1 | Process for producing an optically active amide from an alpha, beta-unsaturated amide derivative in the presence of a transition metal complex containing a phosphine-phosphorane compound and a transition metal | Takasago International Corporation (JP) | 2003-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120067-A1 | Process for producing optically active amide from alpha beta- unsaturated amide derivative in the presence of transition metal complex containing phosphine-phosphorane compound and transition metal | PHOSPHO1, NAAA, DEGS1 | LMNA 3730/4885ALDH1A1 1510/4885KDM4E 4438/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | LMNA 4386/4885ALDH1A1 1079/4885KDM4E 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.